Niagen Bioscience

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NAGE and other ETFs, options, and stocks.

About NAGE

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). 

CEO
Robert N. Fried
CEORobert N. Fried
Employees
117
Employees117
Headquarters
Los Angeles, California
HeadquartersLos Angeles, California
Founded
1999
Founded1999
Employees
117
Employees117

NAGE Key Statistics

Market cap
301.85M
Market cap301.85M
Price-Earnings ratio
18.23
Price-Earnings ratio18.23
Dividend yield
Dividend yield
Average volume
1.14M
Average volume1.14M
High today
$4.07
High today$4.07
Low today
$3.79
Low today$3.79
Open price
$3.93
Open price$3.93
Volume
408.13K
Volume408.13K
52 Week high
$14.69
52 Week high$14.69
52 Week low
$3.79
52 Week low$3.79

Stock Snapshot

Niagen Bioscience(NAGE) stock is priced at $3.79, giving the company a market capitalization of 301.85M. It carries a P/E multiple of 18.23.

On 2026-05-12, Niagen Bioscience(NAGE) stock traded between a low of $3.79 and a high of $4.07. Shares are currently priced at $3.79, which is 0.0% above the low and -6.9% below the high.

The Niagen Bioscience(NAGE)'s current trading volume is 408.13K, compared to an average daily volume of 1.14M.

In the last year, Niagen Bioscience(NAGE) shares hit a 52-week high of $14.69 and a 52-week low of $3.79.

In the last year, Niagen Bioscience(NAGE) shares hit a 52-week high of $14.69 and a 52-week low of $3.79.

NAGE News

Simply Wall St 3d
A Look At Niagen Bioscience Valuation After Q1 2026 Beat And Niagen Plus Telehealth Launch

Niagen Bioscience (NAGE) is back on investors’ radar after reporting Q1 2026 results that exceeded consensus estimates, alongside the launch of its Niagen Plus...

A Look At Niagen Bioscience Valuation After Q1 2026 Beat And Niagen Plus Telehealth Launch
TipRanks 5d
Niagen Bioscience price target lowered to $12 from $13 at Roth Capital

Roth Capital lowered the firm’s price target on Niagen Bioscience (NAGE) to $12 from $13 and keeps a Buy rating on the shares. The company’s Q1 results exceeded...

TipRanks 6d
Niagen Bioscience Reports Q1 Results, Updates 2026 Outlook

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

People also own

Based on the portfolios of people who own NAGE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.